SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Neela D Goswami, Ephraim L Tsalik, Susanna Naggie, William C Miller, John R Horton, Christopher D Pfeiffer, Charles B Hicks, A cross-sectional analysis of HIV and hepatitis C clinical trials 2007 to 2010: the relationship between industry sponsorship and randomized study design, Trials, 2014, 15, 1, 31

    CrossRef

  2. 2
    Sun-Wei Guo, An overview of the current status of clinical trials on endometriosis: issues and concerns, Fertility and Sterility, 2014, 101, 1, 183

    CrossRef

  3. 3
    David D. Kim, Jean Y. Tang, John P.A. Ioannidis, Network geometry shows evidence sequestration for medical vs. surgical practices: treatments for basal cell carcinoma, Journal of Clinical Epidemiology, 2014, 67, 4, 391

    CrossRef

  4. 4
    C. M. Faggion, M. Atieh, D. G. Zanicotti, Reporting of sources of funding in systematic reviews in periodontology and implant dentistry, BDJ, 2014, 216, 3, 109

    CrossRef

  5. 5
    John P. A. Ioannidis, Fotini B. Karassa, Eric Druyts, Kristian Thorlund, Edward J. Mills, Biologic agents in rheumatology: unmet issues after 200 trials and $200 billion sales, Nature Reviews Rheumatology, 2013, 9, 11, 665

    CrossRef

  6. 6
    Sarah Burningham, Adam Ollenberger, Timothy Caulfield, Commercialization and Stem Cell Research: A Review of Emerging Issues, Stem Cells and Development, 2013, 22, S1, 80

    CrossRef

  7. 7
    Pritesh N. Bodalia, Anthony M. Grosso, Reecha Sofat, Raymond J. MacAllister, Liam Smeeth, Soraya Dhillon, Juan-Pablo Casas, David Wonderling, Aroon D. Hingorani, Comparative efficacy and tolerability of anti-epileptic drugs for refractory focal epilepsy: systematic review and network meta-analysis reveals the need for long term comparator trials, British Journal of Clinical Pharmacology, 2013, 76, 5
  8. 8
    Adriano R. Tonelli, Joe Zein, John P.A. Ioannidis, Geometry of the Randomized Evidence for Treatments of Pulmonary Hypertension, Cardiovascular Therapeutics, 2013, 31, 6
  9. 9
    John P.A. Ioannidis, In reply II—Reversal of Medical Practices, Mayo Clinic Proceedings, 2013, 88, 10, 1184

    CrossRef

  10. 10
    A. G. Dunn, F. T. Bourgeois, E. Coiera, Industry influence in evidence production, Journal of Epidemiology & Community Health, 2013, 67, 7, 537

    CrossRef

  11. 11
    Anna-Bettina Haidich, Dimitrios Pilalas, Despina G. Contopoulos-Ioannidis, John P.A. Ioannidis, Most meta-analyses of drug interventions have narrow scopes and many focus on specific agents, Journal of Clinical Epidemiology, 2013, 66, 4, 371

    CrossRef

  12. You have free access to this content12
    Emmanuel Stamatakis, Richard Weiler, John P.A. Ioannidis, Undue industry influences that distort healthcare research, strategy, expenditure and practice: a review, European Journal of Clinical Investigation, 2013, 43, 5
  13. 13
    Ludovic Trinquart, Gilles Chatellier, Philippe Ravaud, Adjustment for reporting bias in network meta-analysis of antidepressant trials, BMC Medical Research Methodology, 2012, 12, 1, 150

    CrossRef

  14. 14
    Ali A Alkhafaji, Ludovic Trinquart, Gabriel Baron, Moïse Desvarieux, Philippe Ravaud, Impact of evergreening on patients and health insurance: a meta analysis and reimbursement cost analysis of citalopram/escitalopram antidepressants, BMC Medicine, 2012, 10, 1, 142

    CrossRef

  15. 15
    Adam G. Dunn, Blanca Gallego, Enrico Coiera, Industry influenced evidence production in collaborative research communities: A network analysis, Journal of Clinical Epidemiology, 2012, 65, 5, 535

    CrossRef

  16. 16
    Adam G Dunn, Jeffrey Braithwaite, Blanca Gallego, Richard O Day, William Runciman, Enrico Coiera, Nation-scale adoption of new medicines by doctors: an application of the Bass diffusion model, BMC Health Services Research, 2012, 12, 1, 248

    CrossRef

  17. 17
    Orestis A. Panagiotou, John P.A. Ioannidis, Primary study authors of significant studies are more likely to believe that a strong association exists in a heterogeneous meta-analysis compared with methodologists, Journal of Clinical Epidemiology, 2012, 65, 7, 740

    CrossRef

  18. 18
    David Hui, Joseph Arthur, Shalini Dalal, Eduardo Bruera, Quality of the supportive and palliative oncology literature: a focused analysis on randomized controlled trials, Supportive Care in Cancer, 2012, 20, 8, 1779

    CrossRef

  19. 19
    David Hui, Akhila Reddy, Henrique A. Parsons, Eduardo Bruera, Reporting of Funding Sources and Conflict of Interest in the Supportive and Palliative Oncology Literature, Journal of Pain and Symptom Management, 2012, 44, 3, 421

    CrossRef

  20. 20
    A G Dunn, F T Bourgeois, S Murthy, K D Mandl, R O Day, E Coiera, The Role and Impact of Research Agendas on the Comparative-Effectiveness Research Among Antihyperlipidemics, Clinical Pharmacology & Therapeutics, 2012, 91, 4, 685

    CrossRef

  21. 21
    Mikkel Christensen, Filip K Knop, The unobtainable placebo: control of independent clinical research by industry?, The Lancet, 2012, 379, 9810, 30

    CrossRef

  22. 22
    Evangelos C. Rizos, Georgia Salanti, Dimitrios P. Kontoyiannis, John P.A. Ioannidis, Homophily and co-occurrence patterns shape randomized trials agendas: illustration in antifungal agents, Journal of Clinical Epidemiology, 2011, 64, 8, 830

    CrossRef

  23. 23
    John P. A. Ioannidis, Meta-research: The art of getting it wrong, Research Synthesis Methods, 2010, 1, 3-4
  24. 24
    Andreas Lundh, Sergio Sismondo, Joel Lexchin, Octavian A Busuioc, Lisa Bero, Industry sponsorship and research outcome, The Cochrane Library,
  25. 25
    Benjamin Djulbegovic, Ambuj Kumar, Paul P Glasziou, Rafael Perera, Tea Reljic, Louise Dent, James Raftery, Marit Johansen, Gian Luca Di Tanna, Branko Miladinovic, Heloisa P Soares, Gunn E Vist, Iain Chalmers, New treatments compared to established treatments in randomized trials, The Cochrane Library,